<?xml version="1.0" encoding="UTF-8"?>
<p>Among several promising regimens, combination treatment with docetaxel, cisplatin and S-1 (DCS) had received attention for its efficacy and safety in patients with metastatic gastric cancer (
 <xref rid="ref8" ref-type="bibr">8</xref>,
 <xref rid="ref9" ref-type="bibr">9</xref>) until the JCOG 1013 study denied the superiority of DCS therapy over cisplatin plus S-1 (CS) therapy in 2019 (
 <xref rid="ref10" ref-type="bibr">10</xref>). Based on this background, we conducted a multi-institutional phase II trial of preoperative chemotherapy with DCS to evaluate the efficacy and safety in gastric cancer patients with type 4 tumors, large type 3 tumors or bulky lymph node metastasis.
</p>
